SH2D1B | OmnibusX

Name	Number of supported studies	Average coverage
natural killer cell	30 studies	34% ± 14%	Explore
CD16-positive, CD56-dim natural killer cell, human	16 studies	39% ± 13%	Explore
CD16-negative, CD56-bright natural killer cell, human	15 studies	33% ± 14%	Explore
mature NK T cell	5 studies	28% ± 11%	Explore
innate lymphoid cell	3 studies	36% ± 14%	Explore

sc-RNAseq data

Insufficient scRNA-seq data for expression of SH2D1B at tissue level.

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
kidney	71%	49.38	63 / 89	49%	1.12	439 / 901
lung	97%	224.07	559 / 578	23%	0.48	260 / 1155
spleen	100%	593.37	241 / 241	0%	0	0 / 0
muscle	97%	854.83	778 / 803	0%	0	0 / 0
peripheral blood	78%	787.40	725 / 929	0%	0	0 / 0
liver	74%	52.01	167 / 226	4%	0.08	16 / 406
breast	52%	26.25	238 / 459	10%	0.24	113 / 1118
esophagus	32%	56.99	466 / 1445	30%	0.73	54 / 183
intestine	40%	36.68	385 / 966	14%	0.32	74 / 527
adipose	53%	31.09	637 / 1204	0%	0	0 / 0
uterus	16%	7.41	27 / 170	28%	0.73	129 / 459
tonsil	0%	0	0 / 0	42%	1.29	19 / 45
thymus	28%	12.82	181 / 653	4%	0.07	27 / 605
stomach	9%	3.72	34 / 359	18%	0.32	52 / 286
brain	22%	20.26	572 / 2642	3%	0.05	22 / 705
skin	2%	0.86	33 / 1809	20%	1.13	96 / 472
pancreas	0%	0.10	1 / 328	21%	0.41	37 / 178
lymph node	0%	0	0 / 0	17%	0.30	5 / 29
blood vessel	17%	8.00	221 / 1335	0%	0	0 / 0
prostate	16%	7.23	39 / 245	0%	0.00	1 / 502
bladder	5%	1.57	1 / 21	10%	0.19	52 / 504
heart	12%	5.09	104 / 861	0%	0	0 / 0
ovary	2%	0.77	3 / 180	9%	0.16	39 / 430
adrenal gland	1%	0.24	2 / 258	2%	0.03	4 / 230
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
eye	0%	0	0 / 0	0%	0	0 / 80
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

GO_0002250	Biological process	adaptive immune response
GO_0002717	Biological process	positive regulation of natural killer cell mediated immunity
GO_0002366	Biological process	leukocyte activation involved in immune response
GO_0045089	Biological process	positive regulation of innate immune response
GO_0045087	Biological process	innate immune response
GO_0005829	Cellular component	cytosol
GO_0030674	Molecular function	protein-macromolecule adaptor activity
GO_0005515	Molecular function	protein binding

Gene name	SH2D1B
Protein name	SH2 domain-containing protein 1B (EWS/FLI1-activated transcript 2) (EAT-2)
Synonyms	EAT2
Description	FUNCTION: Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as CD84, SLAMF1, LY9 and CD244 . In SLAM signaling seems to cooperate with SH2D1A/SAP. Plays a role in regulation of effector functions of natural killer (NK) cells by controlling signal transduction through CD244/2B4 without effecting its tyrosine phosphorylation; downstream signaling involves PLCG1 and ERK activation . Activation of SLAMF7-mediated NK cell function does not effect receptor tyrosine phosphorylation but distal signaling (By similarity). In the context of NK cell-mediated cytotoxicity does not enhance conjugate formation with target cells but stimulates polarization of the microtubule-organizing center and cytotoxic granules toward the NK cell synapse . Negatively regulates CD40-induced cytokine production in dendritic cells downstream of SLAM family receptors probably by inducing activation of the PI3K pathway to inhibit p38 MAPK and JNK activation (By similarity). .
Accessions	ENST00000367929.3 [O14796-1] O14796

SH2D1B report